NEW BRUNSWICK (dpa-AFX) - Johnson & Johnson (JNJ) Friday announced that the
U.S. Food and Drug Administration (FDA) has approved its drug Rybrevant in
combination with chemotherapy as a first-line treatment for patients with
non-small cell lung cancer.

Johnson & Johnson said FDA approved Rybrevant with chemotherapy for the
first-line treatment of patients with locally advanced or metastatic non-small
cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20
insertion mutations as detected by an FDA-approved test.

This FDA action converts the May 2021 accelerated approval of Rybrevant to a
full approval based on the confirmatory Phase 3 Papillon study.

'When aiming for the best possible treatment outcomes, a targeted approach
should be used in the first line for patients with EGFR exon 20 insertion
mutations, as this is a commonly applied practice for patients with NSCLC
harboring other molecular driver alterations,' said Joshua K. Sabari, M.D.*, an
oncologist at NYU Langone's Perlmutter Cancer Center and study investigator.*
'The results observed in the PAPILLON study showed significant improvement in
progression-free survival, supporting the use of this regimen as the potential
standard-of-care in the first-line treatment of these patients.'

Worldwide, lung cancer is one of the most common cancers, with NSCLC making up
80 to 85 percent of all lung cancer cases. Alterations in EGFR are the most
common actionable driver mutations in NSCLC. Clinical data show patients with
EGFR exon 20 insertion mutations generally experience limited benefits with
currently approved third-generation EGFR tyrosine kinase inhibitors and
chemotherapy.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX